1. A 61-year-old man with ischemic cardiomyopathy and a left ventricular ejection fraction (LVEF) of 38% develops sustained monomorphic ventricular tachycardia (VT) in the hospital. He is hemodynamically stable. The team considers antiarrhythmic drug therapy. Which of the following agents is appropriate for acute termination of this arrhythmia given the patient's underlying structural heart disease?
A) Flecainide intravenously, which provides rapid sodium channel block and is preferred in hemodynamically stable VT regardless of ejection fraction
B) Propafenone intravenously, which combines sodium channel and beta-adrenergic blockade and is effective for VT in patients with reduced ejection fraction
C) Amiodarone intravenously, which is effective for VT termination and is safe in patients with structural heart disease and reduced ejection fraction
D) Verapamil intravenously, which slows the ventricular rate through calcium channel blockade and is the agent of choice for stable monomorphic VT in ischemic cardiomyopathy
E) Lidocaine intravenously, which as a Class Ic agent provides the most potent sodium channel block and is therefore preferred for VT in the setting of structural heart disease
ANSWER: C
Rationale:
Amiodarone is the preferred antiarrhythmic agent for acute termination of hemodynamically stable VT in a patient with structural heart disease and reduced ejection fraction. Its multi-class profile (Class I through IV activity) makes it effective against a broad range of ventricular arrhythmias, and critically, it does not carry the contraindication that limits Class Ic agents in structural heart disease. IV amiodarone is guideline-supported for this indication and is the agent most commonly used in this clinical scenario.
Option A: Option A is incorrect: flecainide is a Class Ic agent and is contraindicated in structural heart disease, including ischemic cardiomyopathy with reduced ejection fraction, based on the CAST trial demonstrating excess mortality in post-MI patients; it should not be used here regardless of hemodynamic stability.
Option B: Option B is incorrect: propafenone is also a Class Ic agent (with additional beta-blocking properties) and carries the same contraindication as flecainide in structural heart disease; it is not appropriate in this patient.
Option D: Option D is incorrect: verapamil is contraindicated in VT of unknown origin or in hemodynamically compromised patients; in monomorphic VT with structural heart disease, verapamil risks causing hemodynamic collapse through negative inotropy and should not be used as the primary agent.
Option E: Option E is incorrect: lidocaine is a Class Ib agent, not a Class Ic agent; while lidocaine is a reasonable alternative for VT in the setting of ischemia (where its use-dependent block preferentially affects ischemic tissue), it is not classified as Class Ic and does not provide "the most potent" sodium channel block; that property belongs to Class Ic agents, which are contraindicated here.
2. A 55-year-old woman with paroxysmal atrial fibrillation and no structural heart disease is started on an antiarrhythmic agent for rhythm control. An ECG obtained one week later shows the QRS duration has increased from 88 ms at baseline to 128 ms. Her heart rate is 72 beats per minute and she is asymptomatic. Which of the following agents is most likely responsible for this finding, and what does it indicate?
A) Amiodarone, which prolongs the QRS by blocking potassium channels in ventricular conduction tissue and increasing total ventricular activation time
B) Sotalol, which widens the QRS through combined beta-adrenergic blockade and potassium channel inhibition in the His-Purkinje system
C) Dronedarone, which produces QRS widening as its primary pharmacodynamic effect by selectively blocking sodium channels in the AV node
D) Dofetilide, which causes QRS widening through its potent blockade of IKr channels in ventricular myocytes, reflecting excessive action potential duration prolongation
E) Flecainide, which as a Class Ic agent produces use-dependent sodium channel block that slows phase 0 depolarization in ventricular myocardium and His-Purkinje tissue, widening the QRS as a direct pharmacodynamic effect
ANSWER: E
Rationale:
QRS widening is the pharmacodynamic signature of Class I sodium channel blockade in ventricular and His-Purkinje tissue, and among all antiarrhythmic agents, Class Ic agents produce the most pronounced QRS prolongation because they have the slowest unbinding kinetics. Flecainide is the Class Ic agent used for rhythm control in patients without structural heart disease (the only population in which it is appropriate), and a 40 ms increase in QRS duration at rest (88 to 128 ms) is consistent with its use-dependent sodium channel blocking effect. QRS widening of more than 25% above baseline is a recognized pharmacodynamic marker of Class Ic exposure and warrants monitoring; widening beyond 0.16 to 0.18 seconds signals possible toxicity. This patient is asymptomatic with a modest QRS increase and warrants continued monitoring and review of drug levels and heart rate, but the finding itself is expected.
Option A: Option A is incorrect: amiodarone does have Class I sodium channel blocking properties and can cause modest QRS widening, but it is more prominently associated with QT prolongation (from its dominant Class III potassium channel blocking effect); it is not the agent most associated with pronounced QRS widening at therapeutic doses.
Option B: Option B is incorrect: sotalol's Class II effect (beta-blockade) can slightly widen the QRS at very high doses but is not the mechanism of significant QRS prolongation; sotalol's primary ECG effect is QT prolongation from its Class III potassium channel block.
Option C: Option C is incorrect: dronedarone can cause modest QRS widening from its sodium channel blocking component, but AV nodal selectivity is not its mechanism, and it is not associated with the degree of QRS widening described here at therapeutic doses.
Option D: Option D is incorrect: dofetilide blocks only IKr channels with no meaningful sodium channel blockade; its ECG effect is QT prolongation, not QRS widening; QRS widening from dofetilide would indicate either a misidentified agent or a drug interaction raising dofetilide levels to suprapherapeutic concentrations.
3. A 31-year-old man with Wolff-Parkinson-White (WPW) syndrome is brought to the emergency department with palpitations and dizziness. His ECG shows an irregular wide-complex tachycardia at a ventricular rate of 230 beats per minute. The rhythm is confirmed as pre-excited atrial fibrillation with conduction over the accessory pathway. He is hemodynamically stable. Which of the following represents the correct management?
A) Administer intravenous adenosine 6 mg as a rapid bolus to terminate the arrhythmia through transient AV nodal block, restoring sinus rhythm
B) Administer intravenous diltiazem to slow the ventricular rate through AV nodal calcium channel blockade, buying time for spontaneous conversion
C) Administer intravenous metoprolol to reduce sympathetic drive to the AV node and slow the ventricular response while monitoring for rhythm conversion
D) Administer intravenous procainamide, which slows conduction over the accessory pathway and is the pharmacological agent of choice for hemodynamically stable pre-excited AF
E) Administer intravenous verapamil to achieve rate control through AV nodal blockade while preparing for electrical cardioversion if the patient deteriorates
ANSWER: D
Rationale:
Pre-excited atrial fibrillation in WPW syndrome is a pharmacological emergency requiring careful drug selection. The accessory pathway lacks the decremental conduction properties of the AV node, meaning it can conduct atrial impulses at extremely rapid rates directly to the ventricles. AV nodal blocking agents including adenosine, diltiazem, verapamil, beta-blockers, and digoxin are all contraindicated in this rhythm: by blocking the AV node, they remove the one competing pathway that was partially absorbing some atrial impulses, driving all conduction through the accessory pathway and risking acceleration of the ventricular rate to levels that can cause hemodynamic collapse or degenerate into ventricular fibrillation. Procainamide (Class Ia) is the agent of choice for hemodynamically stable pre-excited AF because it slows conduction velocity in the accessory pathway itself, reducing the rate of impulse transmission to the ventricles. Ibutilide is an alternative. For unstable patients, electrical cardioversion is always first-line.
Option A: Option A is incorrect: adenosine is contraindicated in pre-excited AF; blocking the AV node in this rhythm can precipitate ventricular fibrillation by redirecting all conduction through the accessory pathway.
Option B: Option B is incorrect: diltiazem is an AV nodal calcium channel blocker and is contraindicated in pre-excited AF for the same reason as adenosine; it must not be used here.
Option C: Option C is incorrect: metoprolol is a beta-blocker (Class II agent) and blocks AV nodal conduction through reduction of sympathetic drive; it is contraindicated in pre-excited AF for the same reason as all other AV nodal blocking agents.
Option E: Option E is incorrect: verapamil is among the most dangerous agents in pre-excited AF; in addition to AV nodal blockade, its vasodilatory properties can cause hypotension, and case reports document verapamil-precipitated ventricular fibrillation in WPW patients with pre-excited AF.
4. A 70-year-old woman with atrial fibrillation and chronic kidney disease has a measured creatinine clearance (CrCl) of 36 mL/min. Her cardiologist is considering sotalol for rhythm control. Which of the following best describes the appropriate management of sotalol dosing in this patient?
A) Sotalol can be started at the standard dose of 80 mg twice daily because CrCl above 30 mL/min does not require dose adjustment for this indication
B) Sotalol should be initiated at a reduced dose of 40 mg twice daily with outpatient ECG monitoring every two weeks for the first two months of therapy
C) Sotalol is absolutely contraindicated at any dose when CrCl is below 40 mL/min for the atrial fibrillation indication, and an alternative agent should be selected
D) Sotalol can be initiated at a reduced dose with in-hospital QTc monitoring for a minimum of three days, provided the CrCl is above 40 mL/min; this patient's CrCl of 36 mL/min falls below that threshold, making sotalol contraindicated for this indication
E) Sotalol dosing in renal impairment requires only a reduction in frequency rather than dose; the patient should receive the standard 80 mg dose once daily rather than twice daily, with routine outpatient follow-up
ANSWER: D
Rationale:
Sotalol is eliminated almost entirely by renal excretion, and its label specifies tiered dose adjustment based on CrCl for patients with renal impairment. For the atrial fibrillation indication, sotalol is contraindicated when CrCl falls below 40 mL/min because drug accumulation at that level of renal impairment raises plasma concentrations to a degree that substantially increases the risk of QT prolongation and torsades de pointes. This patient's CrCl of 36 mL/min falls below the 40 mL/min threshold, making sotalol contraindicated for this indication regardless of dose reduction strategies. For patients whose CrCl is above the threshold (40 to 60 mL/min range), the label mandates in-hospital initiation with a minimum of three days of continuous QTc monitoring before discharge, with dose adjustments by CrCl tier.
Option A: Option A is incorrect: the standard dose without adjustment is inappropriate even for patients with CrCl above 40 mL/min who have renal impairment; dose reduction and in-hospital monitoring are required above the threshold, and this patient falls below it.
Option B: Option B is incorrect: outpatient initiation of sotalol in any patient with renal impairment is not label-compliant; the FDA mandates in-hospital initiation with continuous QTc monitoring for sotalol regardless of dose.
Option C: Option C is incorrect in its framing: while the conclusion that sotalol is contraindicated here is correct, Option D provides the more precise and clinically accurate explanation by specifying the threshold and the monitoring requirements that apply above it; Option C's framing implies sotalol is never usable below 40 mL/min without reference to the dose-adjustment and monitoring framework that applies above the threshold.
Option E: Option E is incorrect: the FDA label for sotalol does not support once-daily dosing as the renal adjustment strategy for the AF indication; sotalol's label specifies dose reduction by CrCl tier, not frequency reduction alone, and in any case this patient's CrCl falls below the threshold for any sotalol use.
5. A 58-year-old man has been on oral amiodarone 200 mg daily for three years for recurrent ventricular tachycardia. He presents to his cardiologist for a routine follow-up visit and reports no symptoms. Which of the following monitoring parameters is most important to assess at this visit given the duration of amiodarone therapy?
A) Serum potassium and magnesium, which are depleted by amiodarone's inhibition of renal tubular transporters and must be repleted to prevent torsades de pointes during long-term therapy
B) Thyroid function tests, pulmonary function and chest imaging, liver function tests, ophthalmologic examination, and neurological assessment, reflecting amiodarone's multi-organ toxicity profile in long-term use
C) Serum creatinine and estimated glomerular filtration rate, because amiodarone accumulates in the kidney and causes progressive renal tubular toxicity that requires dose reduction when GFR falls below 45 mL/min
D) Complete blood count with differential, because amiodarone causes dose-dependent bone marrow suppression that is the most common reason for drug discontinuation after three years of therapy
E) Serial ECGs at each visit to assess for progressive QRS widening, which is the primary toxicity marker for long-term oral amiodarone use and predicts subsequent ventricular proarrhythmia
ANSWER: B
Rationale:
Amiodarone has an unusually broad and serious organ toxicity profile that requires systematic monitoring across multiple organ systems during long-term therapy. Thyroid dysfunction (both hypothyroidism and hyperthyroidism) is among the most common adverse effects, occurring in up to 15 to 20 percent of patients over years of therapy, driven by amiodarone's high iodine content and its direct effects on thyroid hormone metabolism; thyroid function tests should be checked at least every six months. Pulmonary toxicity (amiodarone pulmonary toxicity, APT) is the most life-threatening non-cardiac adverse effect, ranging from subacute interstitial pneumonitis to acute respiratory distress syndrome; baseline and periodic chest X-ray and pulmonary function testing are warranted. Hepatotoxicity occurs in a subset of patients and liver function tests should be monitored periodically. Corneal microdeposits occur in nearly all patients on long-term therapy (usually asymptomatic) but a small percentage develop visual disturbance from optic neuropathy, warranting ophthalmologic surveillance. Peripheral neuropathy and other neurological effects (tremor, ataxia, sleep disturbance) are well described. The breadth of this monitoring requirement reflects amiodarone's accumulation in multiple tissue compartments over its multi-week half-life.
Option A: Option A is incorrect: amiodarone does not cause clinically significant depletion of potassium or magnesium through renal tubular mechanisms; while electrolyte monitoring is generally appropriate in patients on antiarrhythmics, it is not the primary monitoring concern for amiodarone toxicity.
Option C: Option C is incorrect: amiodarone does not cause progressive renal tubular toxicity and does not require dose adjustment for renal impairment; it is hepatically metabolized and is actually the preferred antiarrhythmic in severe renal impairment for this reason.
Option D: Option D is incorrect: bone marrow suppression is not a recognized toxicity of amiodarone and is not a reason for drug discontinuation; this description does not match amiodarone's known adverse effect profile.
Option E: Option E is incorrect: QRS widening is more characteristic of Class Ic agent toxicity than long-term oral amiodarone; while amiodarone has some sodium channel blocking activity, progressive QRS widening is not the primary monitoring target for oral amiodarone toxicity surveillance.
6. A 67-year-old man with atrial fibrillation is initiated on dofetilide for rhythm control. He is admitted to hospital for the mandatory initiation period with continuous telemetry. On day two, his QTc interval is measured at 530 ms. His baseline QTc prior to initiation was 420 ms. Which of the following is the correct next step?
A) Continue dofetilide at the current dose and recheck the QTc in 24 hours, as a QTc of 530 ms is within the acceptable range for dofetilide initiation monitoring
B) Reduce the dofetilide dose by one tier according to the prescribing label and continue in-hospital monitoring with repeat QTc assessment after the next two doses
C) Discontinue dofetilide immediately, as a QTc exceeding 500 ms or an increase of more than 15 percent above baseline during initiation requires drug withdrawal per the prescribing label
D) Add intravenous magnesium sulfate to suppress the QT prolongation and allow dofetilide to continue at the current dose, as magnesium is the standard co-treatment during dofetilide initiation
E) Perform urgent electrical cardioversion to restore sinus rhythm before reassessing the QTc, because accurate QTc measurement requires a sinus mechanism and the AF-associated rate variability renders the reading unreliable
ANSWER: C
Rationale:
Dofetilide requires mandatory in-hospital initiation with continuous QTc monitoring because of its propensity to cause torsades de pointes through IKr blockade. The prescribing label specifies that if the QTc exceeds 500 ms at any point during the initiation period (or 550 ms in patients with ventricular conduction abnormalities), dofetilide must be discontinued. This patient's QTc of 530 ms exceeds the 500 ms threshold and mandates immediate drug discontinuation. The 110 ms increase from baseline (420 to 530 ms) also represents more than a 20 percent increase, which itself would warrant action. Continuing or dose-reducing at a QTc of 530 ms is not label-compliant and exposes the patient to substantial risk of TdP.
Option A: Option A is incorrect: a QTc of 530 ms is not within the acceptable range for dofetilide initiation; the 500 ms threshold is the discontinuation trigger, not a monitoring threshold to observe for another 24 hours.
Option B: Option B is incorrect: dose reduction is an appropriate response if the QTc exceeds 15 percent of baseline at the two-hour post-dose assessment during initiation, but when the QTc exceeds 500 ms at any point, the label requires discontinuation rather than dose adjustment.
Option D: Option D is incorrect: intravenous magnesium is the treatment for active torsades de pointes, not a prophylactic co-treatment to permit continued dofetilide administration in the setting of a QTc above the safety threshold; magnesium does not override the discontinuation requirement.
Option E: Option E is incorrect: the QTc in atrial fibrillation is measured using the RR interval of the preceding beat (or the mean RR) and is a validated measurement; the presence of AF does not invalidate QTc assessment and does not change the management requirement at a QTc of 530 ms.
7. A 63-year-old man with a history of myocardial infarction 18 months ago and an LVEF of 42% develops frequent symptomatic premature ventricular contractions (PVCs), occurring at a burden of 22% on 24-hour Holter monitoring. He has no history of sustained ventricular tachycardia. His internist considers prescribing flecainide to suppress the PVCs and improve his symptoms. Which of the following best explains why flecainide is not appropriate in this patient?
A) Flecainide is ineffective for PVC suppression in patients with ischemic heart disease because its use-dependent block is overcome by the elevated sympathetic tone present in post-MI patients, resulting in no meaningful reduction in PVC burden
B) Flecainide is not FDA-approved for PVC suppression in any patient population regardless of structural heart disease status, making any use in this setting investigational and not standard of care
C) Flecainide would suppress the PVCs effectively but requires mandatory co-administration with an AV nodal blocking agent to prevent accelerated ventricular conduction, and this patient cannot safely receive such combination therapy given his reduced ejection fraction
D) Flecainide is contraindicated only if LVEF is below 35%; this patient's LVEF of 42% is above that threshold, and flecainide may be prescribed with careful dose titration and ECG monitoring in this clinical setting
E) Flecainide is contraindicated in this patient because he has structural heart disease from prior myocardial infarction; the CAST trial demonstrated that Class Ic agents significantly increase mortality in post-MI patients despite effective PVC suppression, and this contraindication applies to all patients with structural heart disease regardless of current ejection fraction
ANSWER: E
Rationale:
The CAST trial is among the most important pharmacological lessons in cardiovascular medicine. It enrolled post-MI patients with asymptomatic or mildly symptomatic ventricular arrhythmias and randomized them to flecainide, encainide, or placebo. Both active agents effectively suppressed PVCs but significantly increased arrhythmic death and total mortality compared with placebo. The trial established definitively that PVC suppression is a surrogate endpoint that does not translate to survival benefit and that Class Ic agents are proarrhythmic in the setting of structural heart disease. Critically, this contraindication is not ejection-fraction dependent; it applies to any patient with structural heart disease, including this patient whose LVEF of 42% is above 35%. The post-MI substrate of ischemic fibrosis and heterogeneous conduction creates the re-entrant substrate that Class Ic agents worsen through use-dependent conduction slowing. For this patient, catheter ablation of the PVC focus or a Class III agent (with appropriate monitoring) would be considerations for symptomatic PVC management.
Option A: Option A is incorrect: flecainide does suppress PVCs effectively in post-MI patients; this was precisely the finding of CAST; the problem is not inefficacy but increased mortality despite efficacy.
Option B: Option B is incorrect: flecainide is FDA-approved for PVC suppression and for AF rhythm control in patients without structural heart disease; it is not restricted to investigational use, but its use in structural heart disease is contraindicated.
Option C: Option C is incorrect: the requirement for an AV nodal blocking agent co-administration applies to flecainide used for AF rhythm control (to prevent rapid AV conduction if flutter develops), not for PVC suppression; and reduced ejection fraction is not a contraindication to beta-blockers specifically.
Option D: Option D is incorrect: the CAST contraindication is not ejection-fraction gated; the substrate for proarrhythmia is the structural heart disease itself (ischemic fibrosis, heterogeneous conduction), not the degree of systolic dysfunction; no preserved-EF threshold exempts a post-MI patient from this contraindication.
8. A 44-year-old woman presents with a narrow-complex regular tachycardia at 190 beats per minute. Vagal maneuvers have no effect. Adenosine 6 mg IV is administered as a rapid bolus and the tachycardia is not terminated, though a brief period of AV block is visible on the monitor during which underlying atrial activity at a rate of 250 beats per minute is revealed before the ventricular rate resumes at 125 beats per minute (2:1 conduction). What does this response to adenosine indicate?
A) The rhythm is atrial flutter; adenosine successfully unmasked the flutter waves by transiently blocking the AV node, and the tachycardia is not AV nodal re-entrant tachycardia since the circuit does not depend on AV nodal conduction
B) The adenosine dose was inadequate; repeating with 12 mg will achieve complete and sustained AV block sufficient to terminate the re-entrant circuit and restore sinus rhythm
C) The patient has WPW syndrome with pre-excited tachycardia; the adenosine response confirms that the tachycardia relies on the accessory pathway rather than the AV node and that AV nodal blocking agents are now indicated for long-term management
D) The rhythm is atrioventricular nodal re-entrant tachycardia (AVNRT); the adenosine unmasked re-entrant P waves but was insufficient to terminate the circuit, and the appropriate next step is to administer a calcium channel blocker
E) The adenosine response confirms atrial tachycardia arising from an automatic focus; the AV block confirmed that the atrial rate is independent of the ventricular rate, and the tachycardia will not respond to agents that work at the AV node
ANSWER: A
Rationale:
Adenosine's utility in diagnosing arrhythmias extends beyond its therapeutic role in terminating AV nodal re-entrant tachycardias. When adenosine is administered during a tachycardia that depends on the AV node as part of its circuit (AVNRT, AVRT), the resulting AV block terminates the arrhythmia entirely. However, when the tachycardia arises from an automatic or re-entrant atrial focus and does not depend on AV nodal conduction for perpetuation, adenosine produces transient AV block that reveals the underlying atrial activity without terminating the arrhythmia. In this case, adenosine revealed atrial activity at 250 beats per minute with 2:1 AV conduction, which is the classic presentation of typical atrial flutter (flutter rate approximately 250 to 300 beats per minute, often conducted at 2:1 to produce a ventricular rate of 125 to 150 beats per minute). The flutter circuit is confined to the right atrium and does not depend on AV nodal conduction, so AV nodal block does not terminate it. Management of atrial flutter focuses on rate control (AV nodal blockers to control ventricular rate), rhythm control (electrical cardioversion, ibutilide, or catheter ablation of the cavotricuspid isthmus), and anticoagulation based on stroke risk.
Option B: Option B is incorrect: the adenosine dose was not inadequate; the response clearly revealed the underlying atrial mechanism, indicating that the arrhythmia is not AV-nodal dependent; a higher dose would produce longer AV block but would not terminate the flutter circuit.
Option C: Option C is incorrect: the response is not consistent with WPW pre-excited tachycardia; in pre-excited tachycardia, adenosine would either terminate the arrhythmia (if AV node is part of the circuit) or be dangerous (if pre-excited AF, where AV block accelerates accessory pathway conduction); the revealed atrial rate and 2:1 conduction pattern point to flutter, not WPW.
Option D: Option D is incorrect: AVNRT would be terminated by adenosine, not merely unmasked; the failure to terminate and the revealed regular atrial activity at 250 beats per minute with a consistent flutter wave morphology excludes AVNRT.
Option E: Option E is incorrect: while automatic atrial tachycardia can also be unmasked by adenosine in a similar fashion, the revealed atrial rate of 250 beats per minute with regular flutter waves and 2:1 conduction is characteristic of atrial flutter, not focal atrial tachycardia (which typically has a rate of 130 to 200 beats per minute with a P-wave morphology distinct from the sawtooth pattern of flutter).
9. A 66-year-old man is diagnosed with atrial fibrillation during a routine cardiology appointment. He has had palpitations for approximately eight months, suggesting the AF duration is within the past year. He has hypertension, no structural heart disease, and an LVEF of 60%. He is asymptomatic at rest with a ventricular rate of 74 beats per minute on metoprolol. His cardiologist discusses the choice between continuing rate control alone versus pursuing early rhythm control. Based on current evidence, which of the following best supports offering this patient early rhythm control?
A) Early rhythm control is indicated in this patient because rate control with metoprolol is insufficient to prevent AF-induced cardiomyopathy at a resting rate of 74 beats per minute, and only sinus rhythm restoration can preserve long-term ventricular function
B) Early rhythm control is supported by the AFFIRM trial, which demonstrated that rhythm control produces a significant reduction in stroke risk compared with rate control, making it the preferred strategy in patients with hypertension and no structural heart disease
C) Early rhythm control is not indicated in asymptomatic patients with controlled ventricular rates; the standard of care is to continue rate control and reassess for symptoms before considering antiarrhythmic therapy
D) Early rhythm control is supported by the EAST-AFNET 4 trial, which demonstrated that rhythm control initiated within 12 months of AF diagnosis significantly reduced a composite of cardiovascular death, stroke, and heart failure hospitalization compared with usual care, independent of symptom burden
E) Early rhythm control is indicated only in patients with symptomatic AF; asymptomatic patients such as this one should be managed with rate control indefinitely because antiarrhythmic drug toxicity outweighs any potential cardiovascular benefit in this population
ANSWER: D
Rationale:
The EAST-AFNET 4 trial, published in 2020 in the New England Journal of Medicine, randomized over 2,700 patients with early AF (diagnosed within the prior 12 months) and cardiovascular risk factors to early rhythm control versus usual care (rate control with rhythm control reserved for symptomatic patients). Early rhythm control significantly reduced the primary composite endpoint of cardiovascular death, stroke, or hospitalization for heart failure or acute coronary syndrome, with a hazard ratio of 0.79 after a median follow-up of five years. Crucially, this benefit was observed regardless of baseline symptom status, meaning that even asymptomatic patients with early AF and cardiovascular risk factors such as this patient benefited from early rhythm control. This trial reframed the rate versus rhythm debate established by AFFIRM and supports offering rhythm control discussions to patients with recently diagnosed AF and cardiovascular risk factors, not restricting rhythm control to symptomatic patients.
Option A: Option A is incorrect: at a resting ventricular rate of 74 beats per minute, rate control is adequate by current definitions; tachycardia-induced cardiomyopathy requires sustained elevated rates, typically above 100 beats per minute; this patient is not at immediate risk from rate-related cardiomyopathy.
Option B: Option B is incorrect: the AFFIRM trial did not demonstrate that rhythm control reduces stroke risk compared with rate control; in fact, AFFIRM found no difference in overall mortality or stroke between the two strategies and established that rhythm control does not replace anticoagulation; the EAST-AFNET 4 trial is the evidence that supports early rhythm control for cardiovascular event reduction.
Option C: Option C is incorrect: this option reflects the pre-EAST-AFNET 4 paradigm; current evidence supports offering early rhythm control to appropriately selected patients regardless of symptom burden.
Option E: Option E is incorrect: symptom status is not the sole criterion for rhythm control decision-making after EAST-AFNET 4; cardiovascular risk factor burden and early AF diagnosis are the primary eligibility criteria for early rhythm control benefit.
10. A 49-year-old woman with paroxysmal atrial fibrillation and no structural heart disease was started on flecainide 100 mg twice daily four weeks ago. She now presents to the emergency department with a regular wide-complex tachycardia at 160 beats per minute. Her blood pressure is 108/72 mmHg. A 12-lead ECG shows a wide QRS tachycardia with a monomorphic morphology that looks like ventricular tachycardia. Which of the following best explains the mechanism of this new arrhythmia?
A) Flecainide has caused direct myocardial toxicity leading to scar formation and a new macro-reentrant circuit in structurally normal myocardium, producing true ventricular tachycardia as a late complication of prolonged drug therapy
B) Flecainide converted the paroxysmal AF to atrial flutter, and through use-dependent sodium channel block it slowed the flutter rate sufficiently to allow 1:1 AV conduction; the resulting wide QRS is from rate-dependent sodium channel block at the accelerated ventricular rate, mimicking ventricular tachycardia
C) Flecainide caused excessive QT prolongation leading to early afterdepolarizations, which triggered a run of torsades de pointes that has now stabilized into a regular wide-complex rhythm due to the drug's membrane-stabilizing properties
D) Flecainide blocked the AV node, allowing an accelerated junctional escape rhythm to emerge at 160 beats per minute with aberrant conduction through blocked His-Purkinje tissue producing the wide QRS morphology
E) Flecainide caused complete heart block with a ventricular escape rhythm; the regular rate of 160 beats per minute reflects an accelerated idioventricular rhythm driven by catecholamine excess from the patient's underlying anxiety about her arrhythmia
ANSWER: B
Rationale:
This clinical scenario is the classic presentation of flecainide proarrhythmia in a patient being treated for AF rhythm control. Flecainide can convert AF to atrial flutter, which is a recognized transitional rhythm. Once flutter is established, flecainide's use-dependent sodium channel block slows the atrial flutter cycle length from the typical 300 beats per minute to approximately 200 to 240 beats per minute. Critically, flecainide has relatively modest effects on AV nodal conduction compared with its atrial effects, so the slower flutter rate may now fall within the 1:1 AV conduction range, whereas the original faster flutter was conducted at 2:1 or 3:1. At a flutter rate of 200 to 240 beats per minute with 1:1 conduction, the ventricular rate reaches 200 to 240 beats per minute. The QRS is wide because at these faster rates, rate-dependent sodium channel block by flecainide is maximal in ventricular and His-Purkinje tissue, slowing intraventricular conduction and widening the QRS. The resulting ECG pattern of a regular wide-complex tachycardia at 160 beats per minute is indistinguishable from ventricular tachycardia on surface ECG, which is why this complication is both common and dangerous. Management requires AV nodal blockade to restore 2:1 conduction (reducing the ventricular rate immediately) followed by flecainide discontinuation and consideration of direct current cardioversion if hemodynamically unstable. This is precisely why Class Ic agents prescribed for AF are routinely co-prescribed with an AV nodal blocking agent (beta-blocker or non-DHP calcium channel blocker).
Option A: Option A is incorrect: flecainide does not cause myocardial scarring or structural remodeling; its proarrhythmic mechanism is electrophysiological (conduction slowing in flutter with 1:1 AV conduction), not structural, and this is not a late complication of prolonged use.
Option C: Option C is incorrect: flecainide does not cause significant QT prolongation or EAD-mediated torsades de pointes; this is the mechanism of Class III agents and other QT-prolonging drugs; Class Ic agents widen the QRS without substantially prolonging the QT interval.
Option D: Option D is incorrect: flecainide does not block the AV node to a degree that would produce junctional escape rhythms; its primary cardiac effect is on fast-response sodium-channel-dependent tissue (atria, His-Purkinje system, ventricles), not the calcium-channel-dependent AV node.
Option E: Option E is incorrect: flecainide does not cause complete heart block; a ventricular escape rhythm would be expected at 20 to 40 beats per minute, not 160 beats per minute; an accelerated idioventricular rhythm driven by catecholamine excess is not the mechanism here.
11. A 74-year-old man has persistent atrial fibrillation and was recently hospitalized for an exacerbation of heart failure with reduced ejection fraction (HFrEF), LVEF 30%. After stabilization, his cardiologist considers dronedarone for rhythm control given his desire to avoid amiodarone's toxicity profile. Which of the following best explains why dronedarone is not appropriate in this patient?
A) Dronedarone is not appropriate because it requires in-hospital initiation with mandatory QTc monitoring similar to dofetilide, and this patient's recent hospitalization makes re-admission logistically impractical within the required timeframe
B) Dronedarone is not appropriate because it is renally eliminated and this patient's age-related decline in renal function will cause drug accumulation, raising the risk of bradycardia and sinus node dysfunction to unacceptable levels
C) Dronedarone is contraindicated in this patient for two independent reasons: he has HFrEF (LVEF 30%), in which dronedarone was associated with excess mortality in the ANDROMEDA trial, and he has persistent AF, which if classified as permanent would additionally carry the excess mortality risk demonstrated in the PALLAS trial
D) Dronedarone is not appropriate because it is a potent inhibitor of CYP3A4 and will raise serum levels of the patient's beta-blocker to dangerous concentrations, causing severe bradycardia and cardiogenic shock in the setting of his already reduced ejection fraction
E) Dronedarone is not appropriate because it does not achieve adequate plasma concentrations in patients with edematous states due to its extensive volume of distribution, making it pharmacologically ineffective in patients with heart failure and fluid retention
ANSWER: C
Rationale:
Dronedarone carries two categorical contraindications that apply simultaneously to this patient. First, HFrEF: the ANDROMEDA trial enrolled patients with symptomatic heart failure and LVEF below 35% and was stopped early due to significantly increased mortality in the dronedarone group, attributed primarily to worsening heart failure. This patient's LVEF of 30% places him squarely within the population shown to be harmed. Second, persistent or permanent AF: dronedarone is contraindicated in patients with permanent AF, defined as AF in which rhythm restoration is no longer being pursued. For patients with persistent AF (such as this patient), the distinction between persistent and permanent depends on whether cardioversion will be attempted; if this patient's AF is classified or evolves to permanent, the PALLAS trial provides additional evidence of harm, having demonstrated excess cardiovascular events in patients with permanent AF on dronedarone. Even in persistent AF, dronedarone's benefit depends on achieving and maintaining sinus rhythm, and its use in a patient with severe HFrEF carries unacceptable risk based on ANDROMEDA. For this patient, amiodarone remains the most evidence-supported antiarrhythmic if drug therapy is pursued; its toxicity profile requires monitoring but it has not demonstrated excess mortality in HFrEF, unlike dronedarone.
Option A: Option A is incorrect: dronedarone does not require mandatory in-hospital initiation with QTc monitoring; this requirement applies to dofetilide and sotalol, not to dronedarone.
Option B: Option B is incorrect: dronedarone is primarily hepatically metabolized, not renally eliminated; renal function is not the basis of its primary contraindications.
Option D: Option D is incorrect: dronedarone does inhibit CYP3A4 and drug interactions are clinically relevant, but this is a manageable interaction requiring dose adjustment of the co-administered drug; it does not constitute a categorical contraindication in the same way as the HFrEF and permanent AF contraindications.
Option E: Option E is incorrect: dronedarone's pharmacokinetics are not significantly altered by edematous states in a way that renders it pharmacologically ineffective; volume of distribution does affect drug levels, but this is not the reason dronedarone is contraindicated in heart failure.
12. A patient with ventricular tachycardia at a rate of 180 beats per minute is treated with a Class Ic agent. At this rapid rate the drug produces significant QRS widening and effectively suppresses conduction. If the same drug is given to the same patient when the heart rate is 60 beats per minute in sinus rhythm, the QRS widening is substantially less pronounced. Which property of Class I sodium channel blockers best accounts for this observation?
A) Use-dependence: at faster heart rates the diastolic interval shortens, reducing time for drug dissociation from the channel between beats and increasing the net fraction of blocked channels, so channel block and its electrocardiographic manifestations are greater at faster rates
B) Reverse use-dependence: Class I agents paradoxically accumulate more channel block at slower heart rates because drug association is favored during the prolonged diastolic intervals of bradycardia, producing greater QRS widening at low rates
C) First-pass elimination: at faster heart rates cardiac output increases, accelerating hepatic blood flow and reducing first-pass metabolism of the drug, raising plasma concentrations and increasing channel block proportionally to rate
D) Receptor upregulation: sustained rapid firing upregulates sodium channel expression in ventricular myocytes, providing more binding sites for the Class I agent and amplifying its pharmacodynamic effect during tachycardia
E) Saturation kinetics: at slow heart rates the drug binds all available sodium channels, producing maximum block; at faster rates the rapidly cycling channels are partially unavailable for drug binding, paradoxically reducing the degree of block during tachycardia
ANSWER: A
Rationale:
Use-dependence (also called frequency-dependence or rate-dependence) is the pharmacodynamic property of Class I sodium channel blockers whereby the degree of channel block increases at faster firing rates. Class I agents bind to sodium channels in their open or inactivated states and then dissociate during the diastolic interval between action potentials. At faster heart rates, the diastolic interval is shorter, giving drug molecules less time to dissociate before the next action potential arrives. As a result, a greater cumulative fraction of sodium channels remains drug-occupied (blocked) at any given moment during tachycardia compared with sinus rhythm at the same plasma drug concentration. This rate-dependent accumulation of block manifests as greater QRS widening during tachycardia than during bradycardia at the same drug level, exactly as described in this scenario. Use-dependence explains both the therapeutic value of Class I agents (greatest block where it is needed, in rapidly firing arrhythmic tissue) and the proarrhythmic risk (QRS widening can become extreme and create a substrate for ventricular arrhythmias at very fast rates).
Option B: Option B is incorrect: reverse use-dependence is a property associated with Class III potassium channel blockers, not Class I agents; in reverse use-dependence, the drug effect (APD prolongation) is greater at slow heart rates, which is the opposite of what is observed with Class I agents.
Option C: Option C is incorrect: changes in hepatic blood flow with heart rate do not account for acute changes in the degree of sodium channel block; use-dependence is a pharmacodynamic property of the drug-channel interaction, not a pharmacokinetic phenomenon related to drug concentration changes.
Option D: Option D is incorrect: sodium channel expression upregulation does not occur acutely during tachycardia on the timescale relevant to this scenario; receptor expression changes occur over days to weeks, not beat-to-beat.
Option E: Option E is incorrect: this describes the reverse of use-dependence and is pharmacologically incorrect; Class I agents do not saturate all channels at slow rates, and their block increases rather than decreases with rate.
13. A 72-year-old man is admitted to the cardiac care unit with a prolonged QTc of 560 ms after starting a new medication. He develops an episode of polymorphic ventricular tachycardia with a characteristic twisting morphology on telemetry. His blood pressure during the episode is 84/52 mmHg. Which of the following is the correct first-line pharmacological intervention?
A) Intravenous amiodarone 150 mg over 10 minutes, which as the most broadly active antiarrhythmic agent is the drug of choice for any form of ventricular tachycardia including torsades de pointes
B) Intravenous lidocaine 1 to 1.5 mg/kg bolus, which as a Class Ib agent shortens action potential duration and is specifically indicated for polymorphic ventricular tachycardia arising from QT prolongation
C) Intravenous isoproterenol infusion to increase heart rate and shorten the QT interval, which is indicated as first-line therapy for drug-induced torsades de pointes in all patient populations
D) Immediate electrical cardioversion with 200 J synchronized shock, which is the only effective intervention for hemodynamically unstable torsades de pointes and should precede all pharmacological measures
E) Intravenous magnesium sulfate 1 to 2 g over 5 to 10 minutes, which is the first-line pharmacological treatment for torsades de pointes regardless of the patient's serum magnesium concentration
ANSWER: E
Rationale:
Intravenous magnesium sulfate is the first-line pharmacological treatment for torsades de pointes, and this recommendation applies regardless of whether the patient's serum magnesium level is normal or low. The mechanism is not simply magnesium repletion: magnesium inhibits calcium entry through L-type calcium channels and reduces the amplitude of early afterdepolarizations (EADs) that trigger TdP episodes, interrupting the arrhythmia without the proarrhythmic risks of other antiarrhythmics. The standard dose is 1 to 2 g given intravenously over 5 to 10 minutes, and this should be administered promptly in any patient with TdP regardless of hemodynamic status (though unstable patients also require cardioversion). Additional management includes withdrawal of the offending QT-prolonging drug, correction of hypokalemia and hypomagnesemia, and temporary pacing or isoproterenol to increase heart rate (shortening the QT interval and reducing EAD-mediated re-initiation of TdP) if magnesium alone is insufficient or episodes are recurrent.
Option A: Option A is incorrect: amiodarone is contraindicated in TdP because it prolongs the QT interval through Class III potassium channel blockade, potentially worsening the arrhythmia; it is the wrong agent for QT prolongation-mediated polymorphic VT.
Option B: Option B is incorrect: lidocaine is a Class Ib agent that shortens APD and may have some theoretical benefit in TdP by reducing EAD amplitude, but it is not the standard first-line treatment; magnesium is the evidence-based first-line pharmacological intervention.
Option C: Option C is incorrect: isoproterenol can be used to increase heart rate and shorten the QT interval in refractory or recurrent TdP, particularly in acquired long QT syndrome, but it is not universally appropriate as first-line therapy across all patient populations, including those with ischemic heart disease where its use can precipitate ischemia; it is a second-line measure after magnesium.
Option D: Option D is incorrect: while cardioversion is indicated for hemodynamically unstable TdP and should not be withheld in a patient in extremis, the patient described has a blood pressure of 84/52 mmHg but is not described as pulseless or unresponsive; pharmacological treatment with magnesium should be initiated simultaneously with preparation for cardioversion rather than being the sole priority after ruling out all pharmacological measures.
14. A 58-year-old man has sustained re-entrant ventricular tachycardia arising from scar tissue in the left ventricle from a prior myocardial infarction. His electrophysiologist is considering which antiarrhythmic strategy would most effectively interrupt and prevent recurrence of this re-entrant circuit. Which of the following mechanisms best explains how Class III antiarrhythmic agents suppress re-entrant arrhythmias?
A) Class III agents convert unidirectional block within the re-entrant circuit to bidirectional block by accelerating sodium channel recovery kinetics, eliminating the asymmetric conduction that allows the circuit to sustain itself
B) Class III agents eliminate the re-entrant substrate by slowing conduction velocity in both limbs of the circuit simultaneously, reducing the pathway length below the minimum required for self-sustaining re-entry
C) Class III agents interrupt re-entry by hyperpolarizing ventricular myocytes through direct potassium channel activation, raising the resting membrane potential further from threshold and making tissue less susceptible to re-excitation by the circulating wavefront
D) Class III agents suppress re-entry by prolonging the effective refractory period throughout the myocardium; the extended refractory period increases the likelihood that tissue ahead of the circulating wavefront will still be refractory when the impulse arrives, extinguishing the circuit by denying it excitable tissue to re-enter
E) Class III agents prevent re-entry by blocking L-type calcium channels in scar-border zone tissue, eliminating the slow calcium-dependent conduction that sustains the re-entrant circuit in the peri-infarct region
ANSWER: D
Rationale:
Re-entrant circuits depend on finding excitable tissue ahead of the circulating wavefront. For a re-entrant circuit to sustain itself, the impulse must arrive at any given point in the circuit after that tissue has recovered from its previous activation and become re-excitable. If the effective refractory period (ERP) is prolonged, each segment of the circuit remains refractory for a longer portion of the cardiac cycle, making it more likely that when the wavefront returns, the tissue has not yet recovered. If the ERP is prolonged enough, the wavefront arrives at still-refractory tissue and is extinguished, terminating the arrhythmia. Class III agents achieve this by blocking delayed rectifier potassium channels (primarily IKr), delaying phase 3 repolarization and extending the ERP throughout the ventricles. This is the fundamental antiarrhythmic mechanism of Class III agents and explains their efficacy in re-entrant ventricular arrhythmias, though it is also the source of their proarrhythmic risk through QT prolongation and TdP.
Option A: Option A is incorrect: Class III agents do not affect sodium channel recovery kinetics; accelerating sodium channel recovery would actually shorten the refractory period, the opposite of what Class III agents do.
Option B: Option B is incorrect: slowing of conduction velocity by reducing conduction speed throughout the circuit is the mechanism of Class I agents (sodium channel blockers), not Class III; Class III agents prolong refractoriness, not reduce conduction velocity as their primary mechanism.
Option C: Option C is incorrect: Class III agents block potassium channels, which delays repolarization and prolongs the action potential; they do not open potassium channels or hyperpolarize the membrane, which would be the mechanism of agents such as adenosine acting on IKACh.
Option E: Option E is incorrect: L-type calcium channel blockade is the mechanism of Class IV agents; while peri-infarct tissue does have areas of slow calcium-dependent conduction, this is not the target of Class III agents.
15. A 68-year-old man with atrial fibrillation has a creatinine clearance of 18 mL/min from longstanding diabetic nephropathy. His cardiologist needs to select an antiarrhythmic agent for rhythm control. Sotalol and amiodarone are being compared. Which of the following best explains why amiodarone is the preferred agent in this patient?
A) Amiodarone is preferred because it has a shorter half-life than sotalol, allowing more rapid dose adjustment if adverse effects develop in the setting of reduced renal clearance
B) Amiodarone is preferred because it is hepatically metabolized with negligible renal elimination, making its pharmacokinetics essentially unaffected by the degree of renal impairment, while sotalol is almost entirely renally eliminated and is contraindicated at this level of CrCl
C) Amiodarone is preferred because it does not prolong the QT interval and therefore does not carry the risk of torsades de pointes that makes sotalol dangerous in patients with renal failure and electrolyte abnormalities
D) Amiodarone is preferred because it selectively targets scar tissue in diabetic cardiomyopathy, providing superior rhythm control in patients with diabetic nephropathy compared with sotalol's non-selective potassium channel blockade
E) Amiodarone is preferred because it can be initiated safely on an outpatient basis without QTc monitoring in patients with renal impairment, whereas sotalol requires in-hospital initiation that is not practical given this patient's frequent dialysis sessions
ANSWER: B
Rationale:
The pharmacokinetic profiles of amiodarone and sotalol differ fundamentally in their dependence on renal clearance. Sotalol is eliminated almost entirely unchanged by renal excretion, with negligible hepatic metabolism. At a CrCl of 18 mL/min, sotalol clearance is severely reduced, drug accumulates rapidly, plasma concentrations rise to levels that produce dangerous QT prolongation, and the risk of torsades de pointes is substantially elevated. The FDA label contraindication for sotalol at CrCl below 40 mL/min (for the AF indication) applies definitively to this patient. Amiodarone, by contrast, is hepatically metabolized via CYP3A4 with biliary and fecal excretion; renal elimination plays a negligible role in its clearance. Amiodarone's pharmacokinetics are not significantly altered by even severe renal impairment, making it the antiarrhythmic of choice when renal function is severely reduced. While amiodarone carries its own toxicity profile requiring systematic organ monitoring, its safety in severe renal impairment relative to other antiarrhythmics is well established.
Option A: Option A is incorrect: amiodarone has one of the longest half-lives of any drug in clinical use (weeks to months due to extensive tissue accumulation), not a shorter half-life; dose adjustments for amiodarone toxicity are limited by this prolonged half-life, not facilitated by it.
Option C: Option C is incorrect: amiodarone does prolong the QT interval through its Class III potassium channel blocking activity; it is one of the agents that can cause TdP, though less commonly than pure Class III agents like dofetilide or sotalol; the preference for amiodarone here is based on pharmacokinetics (renal vs. hepatic clearance), not absence of QT risk.
Option D: Option D is incorrect: amiodarone does not selectively target diabetic cardiomyopathy tissue; its multi-class mechanism is not tissue-selective in the manner described.
Option E: Option E is incorrect: amiodarone initiation does not require in-hospital QTc monitoring in the same mandatory way as sotalol or dofetilide, but the comparison in this option misrepresents why amiodarone is preferred; the preference is pharmacokinetic (hepatic clearance), not logistical.
16. A 54-year-old woman with persistent atrial fibrillation is started on a Class III antiarrhythmic agent. Her cardiologist explains that the drug's primary antiarrhythmic mechanism involves prolonging the effective refractory period (ERP). She asks why a longer ERP helps prevent her atrial fibrillation from recurring. Which of the following best explains the relationship between ERP prolongation and re-entrant arrhythmia suppression in atrial tissue?
A) A prolonged ERP increases the conduction velocity of sinus node impulses through the atria, allowing normal sinus rhythm to outpace ectopic atrial foci and suppress the triggers that initiate atrial fibrillation
B) A prolonged ERP shortens the action potential duration in atrial tissue, reducing the window during which triggered activity from early afterdepolarizations can initiate atrial fibrillation
C) A prolonged ERP increases the wavelength of the re-entrant impulse (wavelength equals conduction velocity multiplied by refractory period); a longer wavelength means the re-entrant circuit requires more physical space to sustain itself, and if the wavelength exceeds the available atrial path length, the circuit terminates
D) A prolonged ERP reduces the threshold membrane potential of atrial myocytes, making it harder for any given stimulus to trigger an action potential and therefore reducing the excitability of the tissue that sustains atrial fibrillation
E) A prolonged ERP increases the absolute amount of potassium efflux during phase 3 of the action potential, which accumulates extracellularly and hyperpolarizes adjacent cells, creating a wave of suppressed excitability that propagates through the atria and terminates re-entrant circuits
ANSWER: C
Rationale:
The wavelength concept is central to understanding why ERP prolongation suppresses re-entrant arrhythmias. The wavelength of a re-entrant impulse is defined as the product of the conduction velocity and the effective refractory period: wavelength equals conduction velocity multiplied by ERP. For a re-entrant circuit to sustain itself, the path length of the circuit must be at least as long as the wavelength of the circulating impulse. If the wavelength is shorter than the available path length, the wavefront can circulate through tissue that has already recovered, sustaining the arrhythmia. If the wavelength is increased (by prolonging the ERP), the minimum path length required to sustain re-entry increases. If the prolonged wavelength exceeds the physical dimensions of the available atrial tissue, the re-entrant wavefront encounters refractory tissue before completing the circuit and the arrhythmia terminates. In AF, multiple simultaneous re-entrant wavelets require enough atrial mass to support their circuits; ERP prolongation by Class III agents reduces the number of wavelets that can be sustained simultaneously, and if the wavelength becomes long enough relative to atrial size, re-entry cannot be maintained. This is the mechanistic basis for using Class III agents in AF rhythm control.
Option A: Option A is incorrect: ERP prolongation does not increase conduction velocity; conduction velocity is determined primarily by sodium channel availability and membrane excitability, not by the refractory period; Class III agents do not accelerate sinus node impulse conduction.
Option B: Option B is incorrect: Class III agents prolong, not shorten, action potential duration by blocking potassium channels; shortening APD would be the effect of Class Ib agents, and it would not reduce EAD-mediated triggered activity but rather reduce re-entrant circuit sustainability for different reasons.
Option D: Option D is incorrect: ERP prolongation does not reduce the threshold membrane potential; membrane threshold is determined by sodium channel properties; prolonging the ERP means the tissue is refractory (cannot respond to any stimulus), which is distinct from raising or lowering the threshold for excitation.
Option E: Option E is incorrect: extracellular potassium accumulation does occur during action potentials but does not propagate through the atria in the manner described; the mechanism of Class III antiarrhythmic action is intracellular channel block, not extracellular potassium wave propagation.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.